8-K current report · filed Nov 6, 2026

Perspective Therapeutics, Inc. (CATX) 8-K Current Report: November 6, 2026

Item 8.01Item EX-99.1Item EX-99.2CATX overview

Short answer

Perspective Therapeutics, Inc. (CATX) filed an 8-K current report with the SEC on November 6, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). Updated interim Phase 1/2a results for VMT01 melanoma diagnosis and treatment presented at SITC’s 41st Annual Meeting.

Perspective Therapeutics, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 8.01 · Other Events

  • Updated interim Phase 1/2a results for VMT01 melanoma diagnosis and treatment presented at SITC’s 41st Annual Meeting
  • Trial targets unresectable or metastatic melanoma patients with melanocortin 1 receptor tumor expression
  • Results may inform VMT01’s clinical proof-of-concept and development path, but remain interim early-stage data
  • Press release and poster presentation provide the substantive efficacy and safety details in Exhibits 99.1 and 99.2

Item EX-99.1 · Exhibit EX-99.1

  • Phase 1/2a VMT01 melanoma data: 75% disease control at the 3.0 mCi focus dose
  • Two of eight patients achieved partial responses, with one ongoing approximately 40 weeks after first treatment
  • Safety profile favorable across 20 patients: no dose-limiting toxicities, treatment-related serious adverse events, or discontinuations
  • Grade 3 or higher adverse events in five patients, 25%, none treatment-related
  • Continued dose optimization supports further development, but efficacy remains interim and based on a small cohort

Item EX-99.2 · Exhibit EX-99.2

  • Phase I/IIa monotherapy data support continued development of [212Pb]VMT01 in previously treated metastatic melanoma
  • No dose-limiting toxicities among 20 patients, with grade ≥3 and serious TEAEs each affecting 5 participants (25%)
  • Objective response rate 10%, including 2 confirmed partial responses, both in the 3 mCi cohort
  • 3 mCi cohort showed 75% disease control, with 2 additional patients achieving durable stable disease
  • Combination cohorts with nivolumab remain under evaluation, while expansion depends on recommended phase 2 dose selection

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Perspective Therapeutics, Inc. 8-K filings

Get the next CATX 8-K as it lands

Follow CATX for push alerts, or ask the research agent what this filing means.